Cancer Res Treat.  2010 Sep;42(3):180-184.

Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis

• Yoon SH
• Kim KH
• Choi J
• Kim GM
• Kim JH
• Kim HS
• Park YN
• Rha SY

Abstract

The proper dose and schedule of sunitinib have yet to be established for patients with metastatic renal cell carcinoma (RCC) on hemodialysis. We reviewed two patients with metastatic RCC on hemodialysis who had been treated with sunitinib in Yonsei Cancer Center, Yonsei University College of Medicine. Fifty milligrams of sunitinib was administered intermittently after each hemodialysis session (3 or 4 times a week). Overall responses were partial response in both cases. Progression-free survivals were 16 and 6 months, respectively, at the time of reporting (April 2010). Both subjects tolerated the treatment.

Keyword

Renal cell carcinoma; Sunitinib; Renal dialysis

MeSH Terms

Appointments and Schedules
Carcinoma, Renal Cell
Disease-Free Survival
Humans
Indoles
Pyrroles
Renal Dialysis
Indoles
Pyrroles

Figure

• 

  Fig. 1 The pathologic features of recurred lesions. Metastatic lesion of lung in case 1 (H&E, ×200) (A). Metastatic lesion of forearm, skin in case 2 (H&E, ×400) (B).

• 

  Fig. 2 Response evaluation of the CT scans in case 1. Target lesions were right hilar lymph node with 41.7 mm (A) and chest wall mass with 40.9 mm (G). Non-target lesions were multiple lung masses (D). After 2 months of treatment, multiple lung lesions started to decrease (B, E, H). After 13 months of treatment, hilar lymph node decreased to 30.7 mm (C) and chest wall mass became 26.7 mm (I) with 30% of size reduction. Non-target lesions also decreased without any new lesions (F).

• 

  Fig. 3 Response evaluation of the CT scans and bone scans in case 2. Target lesion was right hilar lymph node with 34.4 mm (A). Non-target lesions were multiple lesions of lung (C) and bone (E). After 4 months of treatment, the target lesion decreased to 22.6 mm (B), which was 34% reduction, and non-target lesions also decreased (D, F).

Reference

1. Keith DS, Torres VE, King BF, Zincki H, Farrow GM. Renal cell carcinoma in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994; 4:1661–1669. PMID: 8011975.

2. Hughson MD, Buchwald D, Fox M. Renal neoplasia and acquired cystic kidney disease in patients receiving long-term dialysis. Arch Pathol Lab Med. 1986; 110:592–601. PMID: 3521533.

3. Peces R, Martinez-Ara J, Miguel JL, Arrieta J, Costero O, Gorriz JL, et al. Renal cell carcinoma co-existent with other renal disease: clinico-pathological features in predialysis patients and those receiving dialysis or renal transplantation. Nephrol Dial Transplant. 2004; 19:2789–2796. PMID: 15316098.

4. Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 2010; 21:1395–1403. PMID: 20118214.

5. Escudier B. Sorafenib in kidney cancer. Ann Oncol. 2007; 18(Suppl 9):ix90–ix93. PMID: 17631603.

6. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370:2103–2111. PMID: 18156031.

7. Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, et al. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol. 2007; 25:3958–3964. PMID: 17761980.

8. Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007; 178:1883–1887. PMID: 17868732.

9. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006; 24:25–35. PMID: 16314617.

10. Zastrow S, Froehner M, Platzek I, Novotny V, Wirth MP. Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis. Urology. 2009; 73:868–870. PMID: 19167044.

11. Park CY. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis. Anticancer Drugs. 2009; 20:848–849. PMID: 19644356.

12. Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ, et al. Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat. 2009; 41:67–72. PMID: 19707503.